SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Munch-a-Biotech Today
An SI Board Since December 1998
Posts SubjectMarks Bans
3158 136 0
Emcee:  Biomaven Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2108(SERO) Serologicals to acquire Linco; acquisition to be accretive in Y06Ian@SI-3/23/2006
2107Bayer Prepares Rival Bid For Germany's Schering Bayer Expected to Offer €86 Ian@SI-3/23/2006
2106EDIT: Germany's Schering is expected to accept merger bid from Bayer. Per-sIan@SI-3/23/2006
2105A Rare Takeover Attempt in Germany's Drug Industry [NYT] By MARK LANDLER PuDoc Bones-3/22/2006
2104Pharmos Agrees to Acquire Vela Pharmaceuticals Inc. Wednesday March 15, 8:00 am nigel bates-3/15/2006
2103The cap. of Bioprogress is about £67m. At this rate we'll soon have a nigel bates-3/13/2006
2102Watson to Acquire Andrx For $1.9 Billion, Creating the Third Largest Specialty Pnigel bates-3/13/2006
2101<b> Schering AG Rejects Merck KGaA's $18 Billion Bid </b> onlinDewDiligence_on_SI-3/12/2006
2100One has to read past the headlines to discover that neither MRK nor SGP is involIan@SI-3/12/2006
2099German Drug Maker Schering Expects Merck KGaA to Make Offer [WSJ] By JEANNE WHADoc Bones-3/12/2006
2098Merck Makes Bid for Rival Schering By DAVID RISING, Associated Press Writer 54 mnigel bates-3/12/2006
2097AstraZeneca Is on Prowl Outside Its Own Lab Walls Stale Drug Pipeline Spurs CEODoc Bones-3/9/2006
2096It's been 1:1 for years. Oh well.keokalani'nui-3/7/2006
2095The data is from quote.com. Sometimes they get confused with the ADR-ratios and Biomaven-3/7/2006
2094Peter, not sure what the data feed is...but I have Acambis (ACAM) at ~$410m US mkeokalani'nui-3/7/2006
2093I think ABGX is spoken for... ...and for under $4bn you can rule out MEDX. :-)nigel bates-3/7/2006
2092Here are the companies roughly fitting that $4b to $1b range: <pre> MYL 4Biomaven-3/7/2006
2091UPDATE 1-Pfizer targets deals under $4 bln -vice chairman Tue Mar 7, 2006 1:59 PBiomaven-3/7/2006
2090Skyepharma spat is starting to be fun: (Under "inflated cost base", sonigel bates-3/2/2006
2089Bristol-Myers May Be Ripe For Takeover After Verdict [WSJ] By JOHN CARREYROU FeDoc Bones-2/25/2006
2088Biogen to spend big on acquisitions Thu Feb 23, 2006 8:10 AM ET BOSTON, Feb 22 sim1-2/23/2006
20877:31AM Xenogen to be acquired by Calper Life Sciences (XGEN) 2.89 : Caliper Lifefred hayes-2/13/2006
2086LONDON, UK, 30 January 2006 - SkyePharma PLC (LSE: SKP; Nasdaq: SKYE) announces nigel bates-1/31/2006
2085Serono tight-lipped on talk of Glaxo cut-price bid ZURICH (Reuters) - Swiss bionigel bates-1/30/2006
2084Lawyer Subpoenaed for Guidant Documents <i>BSX still under the "BostDoc Bones-1/28/2006
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News